12916_2022_2605_MOESM1_ESM.docx (695.08 kB)
Additional file 1 of Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
journal contribution
posted on 2022-10-25, 08:27 authored by Dan Liu, Jun Zhou, Yongsheng Wang, Mingjun Li, Haiping Jiang, Yunpeng Liu, Xianli Yin, Minghua Ge, Xiaojun Xiang, Jieer Ying, Jian Huang, Yan-qiao Zhang, Ying Cheng, Zhigang Huang, Xianglin Yuan, Weiqing Han, Dong Yan, Xinshuai Wang, Pan Liu, Linna Wang, Xiaojing Zhang, Suxia Luo, Tianshu Liu, Lin ShenAdditional file 1: Figure S1. Study design. Figure S2. Tumor response of patients in the dose-escalation and dose-expansion phase. Figure S3. Percentage change from baseline in target lesion tumour burden over time in patients with select tumors at the recommended dose (30 mg/kg q3w). Figure S4. Receiver operating characteristic curve analysis of pSmad2 level in tumor cells for ORR per RECIST v1.1. Table S1. Pharmacokinetic parameters following a single infusion. Table S2. Summary of treatment-related adverse events and tumor response by dose in the dose-escalation and dose-expansion phase. Table S3. Characteristics of patients in clinical expansion cohorts by tumor types. Table S4. Serious treatment-related adverse events. Table S5. Tumor response by PD-L1 expression in all clinical expansion cohorts and in gastric cancer cohort. Table S6. Associations between tumor response and pSMAD2 level in clinical expansion cohorts.
